KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) FCF Margin (2016 - 2025)

Jazz Pharmaceuticals has reported FCF Margin over the past 16 years, most recently at 37.86% for Q4 2025.

  • Quarterly results put FCF Margin at 37.86% for Q4 2025, down 7676.0% from a year ago — trailing twelve months through Dec 2025 was 14.77% (down 1954.0% YoY), and the annual figure for FY2025 was 11.66%, down 2264.0%.
  • FCF Margin for Q4 2025 was 37.86% at Jazz Pharmaceuticals, down from 114.61% in the prior quarter.
  • Over the last five years, FCF Margin for JAZZ hit a ceiling of 114.61% in Q3 2025 and a floor of 72.23% in Q2 2025.
  • Median FCF Margin over the past 5 years was 31.17% (2022), compared with a mean of 25.88%.
  • Peak annual rise in FCF Margin hit 7784bps in 2025, while the deepest fall reached -10390bps in 2025.
  • Jazz Pharmaceuticals' FCF Margin stood at 18.71% in 2021, then skyrocketed by 83bps to 34.21% in 2022, then tumbled by -48bps to 17.91% in 2023, then skyrocketed by 117bps to 38.91% in 2024, then tumbled by -197bps to 37.86% in 2025.
  • The last three reported values for FCF Margin were 37.86% (Q4 2025), 114.61% (Q3 2025), and 72.23% (Q2 2025) per Business Quant data.